aHUS in the media

Row over drug listing – September 25, 2014

Text by LACHLAN MOORHEAD BAD blood has developed between the Federal Government and a pharmaceutical company over subsidies for a lifesaving drug. It comes after the News reported in March on concerned mother Linda Van de Loop who was championing for the government to place the drug, Soliris, on the...

read more

Department of Health Media Release: Government Announces Funding Available For Soliris – September 18, 2014

THE HON PETER DUTTON MP MINISTER FOR HEALTH MINISTER FOR SPORT   MEDIA RELEASE 18 September 2014   GOVERNMENT ANNOUNCES FUNDING AVAILABLE FOR SOLIRIS  The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended to the Australian Government that Soliris – the new and novel treatment for atypical Haemolytic Uraemic Syndrome (aHUS)...

read more

Congratulations to NICE for recommending Solirs be funded for all UK patients living with aHUS – September 12, 2014

The aPSGA wishes to extend our most heartfelt congratulations to all aHUS patients living in the UK on NICE’s recent approval of Soliris. On September 3, 2014 the National Institute for Health and Clinical Excellence (NICE) Highly Specialised Technologies Evaluation Committee (EC) reaffirmed the clinically significant value of Soliris (eculizumab)...

read more

Stakeholder statement from June, 2014 regarding PBS listing of Soliris criteria & proposed restrictions – September 11, 2014

The Department of Health (DoH) has released a statement from its stakeholder meeting held June 24, 2014 to discuss the Pharmaceutical Benefits Scheme (PBS) listing of Soliris (eculizumab) for the treatment of atypical haemolytic uraemic syndrome (aHUS). All invited stakeholders participated, including members of the PBAC, nephrologists, haematologists, patients and the...

read more